Marker Therapeutics, Inc.

Category: Featured

Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019

Peter L. Hoang to present a corporate overview at the upcoming Phacilitate Leaders World & World Stem Cell Summit 2019 on January 23, 2019.

Read More

The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

Data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research 2019.

Read More

Marker Therapeutics Provides Updates of its Lead Clinical Programs

The Company has announced a year-end update in five clinical trials using the Company’s therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.

Read More

Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit

President and CEO, Peter L. Hoang, will be participating at the Tumor Targeted Lymphocyte Summit.

Read More

The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting

Data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018).

Read More

Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer

“Over my career, I’ve had the chance to work with many great companies, a number of which have had a major impact within the biotech sector that led to great advances in patient care. However, I believe Marker Therapeutics’ patient data are truly exceptional, generating excellent complete response rates in a meaningful number of patients to date. ,” said Mr. Kim.

Read More

Marker Therapeutics to Present at Three Upcoming Healthcare Conferences

President and CEO, Peter L. Hoang, will be participating in several healthcare conferences this month.

Read More

Marker Therapeutics, Inc. Announces New Executive Appointments

“We are excited and fortunate to have these four highly accomplished professionals join our team,” commented Marker Therapeutics’ President & CEO Peter L. Hoang.

Read More

Marker to Present at Two Upcoming Cellular Therapy Conferences

Marker Therapeutics, Inc. President and CEO, Peter L. Hoang, will be participating in conferences next week.

Read More

TapImmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing

“The closing of this merger marks a significant milestone, since the combined company is well-positioned to become a leader in cancer immunotherapy, with potentially transformative therapies,” said Peter Hoang, CEO of Marker Therapeutics, Inc.

Learn more about Marker Therapeutics, Inc. by going to markertherapeutics.com

Read More